Статья
ГИПОЛИПИДЕМИЧЕСКАЯ ТЕРАПИЯ В АСПЕКТЕ ПРОФИЛАКТИКИ ОСТРЫХ НАРУШЕНИЙ МОЗГОВОГО КРОВООБРАЩЕНИЯ: СУЩЕСТВУЮЩИЕ СТАНДАРТЫ, ДАННЫЕ ДОКАЗАТЕЛЬНОЙ МЕДИЦИНЫ И РЕАЛЬНАЯ ПРАКТИКА
Сердечно-сосудистые заболевания занимают лидирующие позиции в заболеваемости, смертности и инвалидизации в большинстве стран. В структуре смертности от сердечно-сосудистых заболеваний лидируют ишемическая болезнь сердца и мозговой инсульт. В статье рассматриваются вопросы гиполипидемической терапии статинами в аспекте профилактики острого нарушения мозгового кровообращения. Представлены основные факторы риска атеросклероза и их распространенность. Авторами освещаются существующие стандарты применения статинов, данные доказательной медицины, полученные в рандомизированных клинических исследованиях, а также данные реальной клинической практики. Также рассматриваются возможные перспективные направления применения статинов с целью профилактики острого нарушения мозгового кровообращения. К последним можно отнести комбинированную терапию совместно с другими гиполипидемическими средствами, а также препаратами других групп, применение статинов с более ранних возрастов, реализацию на практике плейотропных эффектов статинов. Авторы наглядно демонстрируют, что реальная практика применения статинов существенно отстает от идеальной, отраженной в рекомендациях и рандомизированных клинических исследованиях. Одним их ключевых факторов этого является приверженность врачебным рекомендациям. Представлены основные факторы, которые могут повлиять на повышение приверженности пациентов к приему статинов и повысить эффективность их применения в реальной клинической практике.
1. Atlas Writing Group. European Society of Cardiology: Cardiovascular Disease Statistics 2017. Eur Heart J. 2018;39(7):508-579. doi: 10.1093/eurheartj/ehx628.
2. Heart Disease and Stroke Statistics—2017 Update. A Report From the American Heart Association. Circulation. 2017;135:e146-e603. doi: 10.1161/CIR.0000000000000485.
3. Gaisenok O.V. Scientific session of the general meeting of the members of the RAS "Scientific fundamentals of the effectiveness and safety of medicines". Available at: http://fguobp.ru/stat/newscard/full/Obshaya-kardiologiya-novosti-meditciny/Nauchnaya-sessiya-obshego-s obraniya-chlenov-RAN-Nauchnye/. Checked by Apr 23, 2018 (In Russ.).
4. Bhatt DL, Steg PG, Ohman EM, et al. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA. 2006;295(2):180-9. doi:10.1001/jama.295.2.180
5. Gaisenok OV, Martsevich SY, Kalashnikov SV, et al. The role of duplex scanning of the carotid arteries in the detection of correlations between carotid and coronary atherosclerosis by the results of coronaroangiography in patients with stable angina. Ter Arkhiv. 2012;84(4):35-8. (In Russ.).
6. Gaisenok O.V., Martsevich S.Yu., Kalashnikov S.Yu., et al. Evaluation of the information content of duplex scanning of carotid arteries in the framework of a comprehensive method of verification of the diagnosis of IHD in practical public health. Profilakticheskaja Medicina. 2012; 15 (6): 41-5 (In Russ.).
7. Heiss G, Sharrett AR, Barnes R, et al. Carotid atherosclerosis measured by B-mode ultrasound in populations: associations with cardiovascular risk factors in the ARIC study. Am J Epidemiol. 1991;134(3):250-6.
8. O'Leary DH, Polak JF, Kronmal RA et al. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. N Engl J Med. 1999;340:14-22. doi: 10.1056/NEJM199901073400103.
9. Bots ML, Hoes AW, Koudstaal PJ et al. Common carotid intima-media thickness and risk of stroke and myocardial infarction: the Rotterdam Study. Circulation. 1997;96(5):1432-7. doi: 10.1161/01.CIR.96.5.1432.
10. Dijk JM, van der Graat G, Bots ML et al. Carotid intima-media thickness and the risk of new vascular events in patients with manifest atherosclerotic disease: the SMART study. Eur Heart J. 2006; 24:1971-8. doi: 10.1093/eurheartj/ehl136.
11. Maslyuk OA, Smolentseva IG, Amosova NA, et al. The hospital registry of a stroke in a specialized department for patients with acute impairment of cerebral circulation. Saratovskij Nauchno-Medicinskij Zhurnal. 2014;10(4):819-23. (In Russ.).
12. Cosentino F, Rubattu S, Savoia C. Endothelial dysfunction and stroke. J Cardiovasc Pharmacol. 2001;38 Suppl 2:S75-8.
13. Knottnerus IL, Ten Cate H, Lodder J, et al. Endothelial dysfunction in lacunar stroke: a systematic review. Cerebrovasc Dis. 2009;27(5):519-26. doi: 10.1159/000212672.
14. Roquer J, Segura T, Serena J, Castillo J. Endothelial dysfunction, vascular disease and stroke: the ARTICO study.Cerebrovasc Dis. 2009;27 Suppl 1:25-37. doi: 10.1159/000200439.
15. Athyros VG, Papageorgiou AA, Mercouris BR, et al. Treatment with Atorvastatin to the National Cholesterol Educational Program Goal Versus ‘Usual’ Care in Secondary Coronary Heart Disease Prevention The GREek atorvastatin and Coronaryheart-disease Evaluation (GREACE)Study. Current Medical Research and Opinion. 2002;18(4):220-28.
16. Collins R, Armitage J, Parish S, et al. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20 536 people with cerebrovascular disease or other high-risk conditions. Lancet. 2004;363:757-67. doi: 10.1016/S0140-6736(04)15690-0.
17. Pedersen TR, Kjekshus J, Pyorala K, et al. Effect of simvastatin on ischemic signs and symptoms in the Scandinavian Simvastatin Survival Study. (4S). Am J Cardiol. 1998;81:3335. doi: 10.1016/S0002-9149(97)00904-1.
18. Sever P.S., Dahlof B., Poulter N.R., et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Drugs. 2004; 64 Suppl 2:43-60.
19. Byington R.P., Davis B.R., Plehn J.F., et al. The Prospective Pravastatin Pooling (PPP) Project. Circulation. 2001;103:387-92. doi: 10.1161/01.CIR.103.3.387.
20. Ridker PM. Moving toward new statin guidelines in a post-JUPITER world: principles to consider. Curr Atheroscler Rep. 2009;11(4):249-56.
21. Amarenco P, Goldstein LB, Szarek M, et al. Effects of Intense Low-Density Lipoprotein Cholesterol Reduction in Patients With Stroke or Transient Ischemic Attack. The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Trial. Stroke. 2007;38:3198-3204. doi: 10.1161/STROKEAHA.107.493106.
22. Sillesen H, Amarenco P, Hennerici MG, et al. Atorvastatin reduces the risk of cardiovascular events in patients with carotid atherosclerosis: a secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Stroke. 2008;39:3297-302. doi: 10.1161/STROKEAHA.108.516450.
23. Flint AC, Kamel H, Navi BB, et al. Statin Use During Ischemic Stroke Hospitalization Is Strongly Associated With Improved Poststroke Survival. Stroke. 2012;43(1):147-54. doi: 10.1161/STROKEAHA.111.627729.
24. Ní Chróinín D, Asplund K, Åsberg S, et al. Statin Therapy and Outcome After Ischemic Stroke. Stroke. 2013;44:448-456. doi: 10.1161/STROKEAHA.112.668277.
25. Yusuf S, Islam S, Chow CK, et al. Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey. Lancet. 2011;378:1231-43. doi: 10.1016/S0140-6736(11)61215- 4.
26. Bhatt D.L., Steg P.G., Ohman E.M. et al.; REACH Registry Investigators. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA. 2006;295:180—9. doi: 10.1001/jama.295.2.180.
27. Susekov AV, Zubareva M.Yu., Deev AD, et al. The main results of the Moscow Statin Survey (MSS). Serdtse. 2006;(6):324-8 (In Russ.).
28. Oganov RG, Kukharchuk VV, Arutyunov GP, et al. Persistent dyslipidemia in statin-treated patients: Russian real-world clinical practice data (Russian part of the DYSIS Study). Cardiovascular Therapy and Prevention. 2012;4:70-8 (In Russ.).
29. Martsevich S.Y., Ginzburg M.L., Kutishenko N.P., et al. The LIS study (Lyubertsy study of mortality in patients with acute myocardial infarction). Evaluation of the pharmacotherapy. Part 1. Treatment of patients before myocardial infarction and its influence on hospital mortality rate. Rational Pharmacotherapy in Cardiology. 2012;8(5):681-4. (In Russ.) (In Russ.). doi:10.20996/1819-6446- 2012-8-5-681-684
30. Martsevich S.Y., Kutishenko N.P., Suvorov A.Y., et al. Characteristics of patients with cerebral stroke or transient ischemic attack, included into the LIS-2 register (Lyubertsy study of mortality in patients after stroke). Rational Pharmacotherapy in Cardiology. 2015;11(1):18-24. (In Russ.). doi: 10.20996/1819-6446-2015-11-1-18-24.
31. Boytsov S.A., Loukianov M.M., Yakushin S.S., et al. Drug treatment of patients with the history of acute stroke: data of the pilot phase of the outpatient registry «REGION». Rational Pharmacotherapy in Cardiology. 2017;13(3):346-356. (In Russ.). doi: 10.20996/1819-6446-2017- 13-3-346-356.
32. Order of Ministry of HC&SD №1740n 29.12.2012 «About Approval of Specialized Medical Care Standards for patients with brain infarction». Available at: https://www.rosminzdrav.ru/documents/8970. Checked 23.04.2017. (In Russ.).
33. Order of Ministry of HC&SD №513 01.08.2007 «About Approval of Medical Care Standard for patients with stroke». (In Russ.). Available at: https://www.rosminzdrav.ru/documents/7803-prikazminzdravsotsrazvitiya-rossii-513-ot-1-avgusta-2007-g. Checked 08.01.2018. (In Russ.)
34. Pitt B., Waters D., Brown W.V. et al. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin versus Revascularization Treatment Investigators. N Engl J Med. 1999;341:70-6.
35. Kini AS, Baber U, Kovacic JC, Changes in plaque lipid content after short-term intensive versus standard statin therapy: the YELLOW trial (reduction in yellow plaque by aggressive lipid-lowering therapy). J Am Coll Cardiol. 2013;62(1):21-9. doi: 10.1016/j.jacc.2013.03.058.
36. Ference B.A., Yoo W., Alesh I., et al. Effect of Long-Term Exposure to Lower Low-Density Lipoprotein Cholesterol Beginning Early in Life on the Risk of Coronary Heart Disease. A Mendelian Randomization Analysis. J Am Coll Cardiol 2012; 60(25): 2631-9. doi:10.1016/j.jacc.2012.09.017
37. Drapkina O.M. Combination therapy of high-risk patients in real clinical practice. Results of Synergy study. Part 1. Antihypertensive branch. Rational Pharmacotherapy in Cardiology. 2017;13(2):155- 63. (In Russ.). doi:10.20996/1819-6446-2017-13-2-155-163
38. Drapkina O.M., Lishuta A.S. Using a combination of perindopril, indapamide and rosuvastatin in the treatment of patients with hypertension and dyslipidemia. Rational Pharmacotherapy in Cardiology. 2017;13(4):454-62. (In Russ.). doi:10.20996/1819-6446-2017-13-4-454-462
39. Kato T, Node K. Docosahexaenoic Acid with a statin and endothelial function in patients with coronary artery disease. J Atheroscler Thromb. 2015;22(5):440-1. doi: 10.5551/jat.ED014.
40. Zhang L, Gong D, Li S, Zhou X. Meta-analysis of the effects of statin therapy on endothelial function in patients with diabetes mellitus. Atherosclerosis. 2012;223(1):78-85. doi: 10.1016/j.atherosclerosis.2012.01.031.
41. Westerink J, Deanfield JE, Imholz BP, et al. High-dose statin monotherapy versus low-dose statin/ezetimibe combination on fasting and postprandial lipids and endothelial function in obese patients with the metabolic syndrome: The PANACEA study. Atherosclerosis. 2013;227(1):118-24. doi: 10.1016/j.atherosclerosis.2012.11.028.
42. Sarkar K, Sinha AK, Mehta JL. The role of statins in endothelial dysfunction in hypertension. Curr Opin Cardiol. 2006;21(4):316-21.
43. Filip-Ciubotaru FM, Manciuc C, Foia L. Statins and endothelial dysfunction. Rev Med Chir Soc Med Nat Iasi. 2009;113(4):975-83.
44. Gong X, Ma Y, Ruan Y, Fu G, Wu S. Long-term atorvastatin improves age-related endothelial dysfunction by ameliorating oxidative stress and normalizing eNOS/iNOS imbalance in rat aorta. Exp Gerontol. 2014;52:9-17. doi: 10.1016/j.exger.2014.01.015.
45. Park J, Hwang I, Kim SJ, et al. Atorvastatin prevents endothelial dysfunction in high glucose condition through Skp2-mediated degradation of FOXO1 and ICAM-1.Biochem Biophys Res Commun. 2017 Aug 9. pii: S0006-291X(17)31568-1. doi: 10.1016/j.bbrc.2017.08.023.
46. Garg N, Krishan P, Syngle A. Rosuvastatin improves endothelial dysfunction in ankylosing spondylitis. Clin Rheumatol. 2015;34(6):1065-71. doi: 10.1007/s10067-015-2912-3
47. Oganov RG, Kukharchuk VV, Arutyunov GP, et al on behalf of the DYSIS Study Group. Persistent dyslipidemia in statin-treated patients: Russian real-world clinical practice data (Russian part of the DYSIS Study). Cardiovascular Therapy and Prevention. 2012;11(4):70-8. (In Russ.).
48. Joshua S. Benner, Robert J. Glynn, Helen Mogun, et al. Long-term Persistence in Use of Statin Therapy in Elderly Patients. JAMA. 2002;288(4):455-61. doi:10.1001/jama.288.4.455
49. Hinchcliffe A. Patient Adherence to Treatment with Statins for the Prevention of Cardiovascular Disease. Cardiff: Public Health Wales NHS Trust; 2011.
50. Jackevicius CA, Mamdani M, Tu JV. Adherence With Statin Therapy in Elderly Patients With and Without Acute Coronary Syndromes. JAMA. 2002;288(4):462-7. doi:10.1001/jama.288.4.462
51. Mantel-Teeuwisse AK, Goettsch WG, Klungel OH, et al. Long term persistence with statin treatment in daily medical practice. Heart. 2004;90(9):1065-6. doi: 10.1136/hrt.2003.026187
52. Mann DM, Woodward M, Muntner P, et al. Predictors of nonadherence to statins: A systematic review and meta-analysis. Ann Pharmacother. 2010;44(9):1410-21. doi: 10.1345/aph.1P150.
53. Gaisenok O., Martsevich S., Tripkosh S., Lukina Y. Analysis of lipid-lowering therapy and factors affecting regularity of statin intake in patients with cardiovascular disease enrolled in the PROFILE registry. Rev Port Cardiol. 2015;34 (2):111-6. doi: 10.1016/j.repc.2014.08.021.
54. Muhlestein JB, Horne BD, Bair TL, et al. Usefulness of in hospital prescription of statin agents after angiographic diagnosis of coronary artery disease in improving continued compliance and reducing mortality. Am J Cardiol. 2001;87:257-61. doi: 10.1016/S0002-9149(00)01354-0
55. Chapman RH, Benner JS, Petrilla AA, et al. Predictors of adherence with antihypertensive and lipidlowering therapy. Arch Intern Med. 2005;165(10):1147-52. doi: 10.1001/archinte.165.10.1147
56. Martsevich S.Yu., Gaisenok O. V., Tripkosh S. G., et al. Medical supervision in specialized center and the quality of lipid-lowering therapy in patients with cardiovascular diseases (according to the PROFILE register). Rational Pharmacotherapy in Cardiology. 2013;9 (2):133-137. (In Russ.). doi: 10.20996/1819-6446-2013-9-2-133-137
57. Ageev FT, Fofanova TV, Smirnova MD, et al. Application of methods of technical impact on adherence to therapy in patients with cardiovascular diseases in outpatient practice. The results of the yearly observation. Serdtse. 2012;11(2):67-71. (In Russ.).
58. Temnikova E.A. To the question of the role of the social environment in increasing adherence to the therapy of outpatient patients of senile age. Serdtse. 2012;11(2):72-7. (In Russ.).
59. Schedlbauer A, Davies P, Fahey T. Interventions to improve adherence to lipid lowering medication. Cochrane Database Syst Rev. 2010;(3):CD004371. doi: 10.1002/14651858.CD004371.pub4.